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Abstract

Opioid abuse is a worldwide problem and there are not enough care providers or treatment programs
available to treat the opioid abuse epidemic. Many primary-care nurse practitioners care for patients who are
dependant and/or abuse opioids. Under current legislation, nurse practitioners are not allowed to prescribe the
schedule III medications necessary to treat them, even though they have been made available to primary-care
physicians with some additional training. This paper discusses the effectiveness of opioid substitution therapy
in a primary care setting, the patient population best suited for this therapy, patient satisfaction with primary
care service, and the barriers preventing primary care providers from providing treatment to opioid patients. It
discusses how nurse practitioners can help overcome some of these barriers and improve access to this
underserved population.
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Introduction
Opioid abuse is a worldwide problem for both industrialized and developing countries.

Specifically, the abuse of prescription opiates is on the rise and is a major public health problem in the United
States. 1 Opioid abuse is defined as using an opiate for a nonmedical purpose or using a prescribed opiate

differently (amount, frequency, person prescribed and rational) than it was prescribed by the provider. In 2008,
more than 33 million Americans used a pain reliever for a nonmedical purpose. 2 According to Substance Abuse

and Mental Health Data Archive, 13.7 % of Americans reported abusing pain relievers in their lifetime where
1.6% reported using heroin in 2010. Opioid abuse doubled from 1977-1982, then increased four-fold from

1987-1996.3 “From 1999-2007, unintentional drug overdose deaths associated with prescription opioids rose by
395%.”4(p355) Opioid abuse is now common with adolescents and the Centers for Disease Control estimates
that $9.5 billion was spent in 2005 on costs associated with prescription opioid abuse (POA). They estimate
that societal costs in 2010 have risen up to more than $55 billion.4 This places pain reliever abuse just below
cocaine abuse, second only to Marijuana.5 Primary care providers are frequently faced with this problem as they
treat patients.
Historically, opioid addiction has been managed in the U.S. in specialized treatment centers where
providers replace the abused opioid with methadone. This has been effective in reducing illicit opioid abuse and
retaining patients in treatment.4,6 Currently, methadone for opioid addiction can only be prescribed in treatment
programs certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA).7
However, the availability of these treatment centers has failed to meet the increasing demand created by the
prescription drug dependence explosion. In 2008, only 35% of the 1.7 million opioid-dependent people in the
U.S. were in treatment8, with a total annual cost of 8.6 billion.9 One-third of methadone maintenance clinics

have lengthy waiting lists and many states do not have any clinics at all, especially in rural areas. 2,10,11 Studies
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estimate only 20% of Americans who suffer from opiate addiction have access to methadone maintenance

therapy.2,10 Communities often limit these clinics from opening or expanding, and patients often feel stigmatized
attending them. 2 In response the Drug Addiction Treatment Act of 2000 (DATA 2000) was created, which

enables qualifying physicians to obtain a waiver allowing them to practice medication-assisted opioid addiction

therapy in primary care practice. To qualify, a physician must have a current state medical license, a valid DEA
registration number, and complete at least eight hours of training in the treatment and management of opioidaddicted patients or have special addiction certifications.12
In 2002, two schedule III controlled medications, Subutex (buprenorphine hydrochloride) and Suboxone
(buprenorphine hydrochloride and naloxone hydrochloride), received FDA approval for the treatment of opioid
addiction.12 There is “extensive empirical evidence” that suggests buprenorphine is safe and effective for
treating opioid addiction in a primary care setting, 13(p92) and it has a much lower risk of overdose than
methadone. Buprenorphine is a mu-receptor agonist and a kappa-receptor antagonist; therefore, it has an opioid
effect with no additional effect beyond a certain point (ceiling effect) with increased dosing. It has slow onset of
action, high affinity for receptor sites, and attaches tightly to receptors. This gives it a long half-life and patients
do not experience sedation or euphoria when taking it. It will replace other opioids at receptors sites triggering
withdrawal symptoms in patients who are physically dependent on opioids. As a result, buprenorphine treatment
should not be started until the patient begins withdrawal symptoms. When buprenorphine is combined with
naloxone, the potential for abuse is decreased further. Naloxone is an opioid antagonist and reverses opioid
effects at the mu and kappa-receptor sites. However, it is not absorbed well when ingested orally; therefore, it
has no effect when taken sublingually as prescribed. If a person attempts to abuse Suboxone by crushing it and
injecting it, the naloxone creates a rapid reversal of the opioid effect. This acts as a natural deterrent to abuse
and prevents Suboxone from being used in ways not prescribed or intended.7,14,15

Despite the adoption of DATA 2000 and buprenorphine therapy, primary care opioid addiction therapy
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is severely underutilized. There are few physicians with the waiver to prescribe the medications16 and half of
those are addiction specialists. 17 Many people would benefit if a wider array of physicians would provide this
treatment. 17 Under the current legislation, nurse practitioners (NPs) and physician assistants (PAs) are
prohibited from prescribing these medications, even in the states with controlled substances prescription
authority. This further limits the availability of treating a population already suffering from a “treatment gap”.
18

(p144)
This paper discusses why there is an underutilization of primary care providers in treating opiate

addiction, by comprehensively reviewing past research identifying the patient populations best suited for opiate
addiction therapy in a primary care setting, the effectiveness of primary care providers in treating opiate
addiction, the patient’s preferences of treatment centers, and the barriers preventing primary care physicians
from practicing opiate addiction therapy in their practices. It will discuss how involving NPs can help overcome
these barriers, improve access, cost effectiveness, and reduce the “treatment gap” for people suffering from
opiate addiction. 18
Methods
An electronic search with terms of opiates or opioid, drug abuse or drug addiction or drug dependency
or substance abuse, rehabilitation or treatment or therapy or recovery, and primary care or general practice
was conducted in CINAHL, MEDLINE, and PsycINFO databases. The search was limited to peer-reviewed
articles published in English from 2006 to April, 2013. Abstracts of 303 articles were reviewed to identify
relevant research studies, resulting in eleven on patient populations, four on patient satisfaction, twelve on
effectiveness, and six on barriers.
An electronic search with terms of nurse practitioner or physician assistant or advanced practice,
prescribe, and buprenorphine was also conducted to identify articles calling for a policy change addressing the

lack of privileges of NPs to prescribe buprenorphine from 2006 to April, 2013 in CINAHL, MEDLINE, and
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PsycINFO databases. The search was limited to peer-reviewed articles published in English resulting in five
articles.
Results
The review of literature showed four themes evaluating opioid substitution therapy (OST) in a primary
care setting. The themes include the patient populations best suited for primary care, the effectiveness of OST in
primary care, patient satisfaction with primary care service, and the barriers preventing primary care providers
from providing treatment to opioid dependent patients.
Patient Population
Eleven studies were identified that researched the types of patients seeking OST at primary care
practices. They ranged from 35 to 2,308 subjects. Seven studies were retrospective chart review descriptive
designs, three were descriptive studies, and one was a randomized clinical trial. Ten were performed in the
United States and the subjects were primarily Caucasian, and five studies had fewer than 100 subjects so
generality is limited.
Research shows those seeking office-based buprenorphine treatment is a new type of patient that has not
received drug abuse treatment. 19 Table 1, Demographics of patients entering OST at primary care clinics,
summarizes the descriptive characteristics of these studies. The average age of people entering treatment is 36–
39 years old, 56–80% are male, 45–85% are full-time employed, and 35–75% have no history of prior
methadone maintenance therapy (MMT) or other treatment. On average, they have less than 10 years of opioid
dependence and have lower rates of intravenous drug use. 19-22 Of patients entering OST in a primary care

setting, 81% own their own home or apartment, 21 75–82% have at least a high school degree, 19,22 and the

majority of the patients (68–97%) are Caucasian. 19-27 This type of patient would not typically seek treatment at

a specialized treatment center and does not take the opportunity to receive help for their addiction unless a
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primary care provider is willing to help them.
The type of opioid being abused does not determine if a patient chooses to have therapy in a primary
care clinic. Some patients mostly abuse heroin, 19,20 whereas others primarily abuse prescription opioids. 21 The

number of patients admitted for OST because of prescription opioid abuse (POA) is increasing28; in 2006, POA

admissions were as high as 50% of all patients seeking treatment23 and the escalating OST demand surpasses
the supply of specialized treatment centers.10,29

Increased demand has triggered researchers to take notice of the POA population and several studies

compare how POA users are different from heroin users. There are conflicting or insignificant differences in
race, age, gender, or income type demographic criteria. 23-27 Note that a large study of 2,308 patients who
entered treatment in Washington State, did find that POA are more likely than heroin users to be married

(32.7% versus 20.5%), have children (45% versus 12.7%), and live in stable housing (94.8% versus 77%).25

POA users are more likely to have earned a high school degree than heroin users, 25-27 are much less likely to
abuse opiates intravenously, 23-27 might have an acute or chronic pain history, 24,27 have a history of other

psychological problems requiring treatment, 24-26 and are more likely to abuse other drugs such as sedatives and

antidepressants. 24-27 Despite these co-morbidities, POAs have a lower opiate severity index, which makes them
more likely to benefit from OST23 and are particularly well suited for treatment in a primary care setting.

Effectiveness of OST in Primary Care

Twelve studies identified the effectiveness of OST in a primary care setting. They ranged from 20 to 360
subjects. Four were retrospective descriptive studies, five were randomized controlled or experimental studies,
and three were observational cohort studies. Eleven of the studies were all done in single treatment centers with
convenience sampling and eight had sample sizes of less than 100 subjects so generality is limited. This is the
nature of these types of studies.
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The safety and effectiveness of buprenorphine in primary care is well established. 14,15 A landmark study

testing the safety and effectiveness of buprenorphine/naloxone treatment in an outpatient setting found:

Direct and rapid induction onto buprenorphine-naloxone was safe and well tolerated…Medication
compliance and treatment engagement was high…The safety profile of buprenorphine-naloxone was
excellent…All providers successfully integrated buprenorphine-naloxone into their existing treatment
milieus. Overall, data from the CTN (NIDA’s National Drug Abuse Treatment Clinical Trials Network)
field experience suggest that buprenorphine-naloxone is practical and safe for use in diverse community
treatment settings, including those with minimal experience providing opioid-based pharmacotherapy
and/or medical detoxification for opioid dependence. 30(pS43)
POA patients are significantly more likely to complete treatment than heroin only patients.33 They have higher
opioid negative urine screens and achieved longer duration of continuous opioid abstinence.21,33 Torrington
(2007) reported improvement in 80% of POA users verses 46% improvement in the heroin users in a primary
care setting. 27 Moore (2007) found the dropout rates for heroin users were 24%, combined users were 2%, and
POA only users had a 0% dropout rate when treated in a primary care setting. 31

It is important to note that heroin users are successfully treated in primary care setting as well, just not to the

same degree as POA users. 20,21,24,27,32-35 Heroin users’ treatment outcomes in the primary care setting are

comparable to opioid treatment programs (OTP) in secondary centers, which usually use methadone. 19,31

Retention rates after 1–2 years of buprenorphine therapy are 40–68% regardless of the type of opioid being
abused. 21,35,35 Buprenorphine is significantly more effective in both the POA and heroin abuse populations,

with retention rates of 87.5% and 60% respectively, than it was for patients on clonidine therapy, with retention
rates of 44.4% and 33.3% and twice the number of drug-free urine tests for both populations doing
buprenorphine therapy. 36 Lucas (2010) found primary care clinic patients started therapy faster, remained in

treatment longer, and had fewer opiate positive drug screens than the patients randomized to an OTP. 33 We can

conclude that both heroin and POA populations are well suited for OST in a primary care practice setting. POA

users might have better success rate due the fact that they often come from a more stable home environment and
their addiction might not be as severe.
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The key for deciding whether a provider should prescribe buprenorphine therapy or methadone therapy
may be determined by the individual’s degree of addiction rather than the drug being abused. Although high
dose buprenorphine therapy has shown to be more effective than low dose methadone therapy, it is not as

effective as high dose methadone therapy in the severely addicted patient.3 When patients have used high doses
of opiates for a long period of time, buprenorphine’s partial activation of the mu receptors sites may not be
enough to overcome withdrawal symptoms. Methadone activates the receptor sites fully which may account for
why severely addicted patients have higher retention rates and longer periods of abstinence on this drug.3
Primary care providers may want to consider referring severely addicted patients to OTPs and treating patients
in their office who have had a shorter intensity and duration of addiction.
Unfortunately, opiate addiction is a long term illness and relapse is common. Patients who wean off the
OST frequently cannot sustain abstinence. Studies show that opioid related deaths are lowest while they are on
OST therapy but rise substantially during the first year after treatment has been discontinued.3 These rates are
the same for both MMT and buprenorphine therapy.
Patient Satisfaction
Four studies were identified that explored patient satisfaction with care in a primary care setting. They
ranged from 29 to 142 subjects. Two were observational cohort studies, one had qualitative study interviews of
patients in a randomized clinical trial and the other was a randomized clinical trial. Assessments are largely
subjective in studies like these and each study had generalizability challenges depending on the size or
population targeted in the study.
Patients express high satisfaction with buprenorphine therapy from a primary care setting. 22,34,35

Patients prefer primary care therapy over OTPs because they believe the practitioner is more helpful in dealing
with their problem, the buprenorphine/naloxone medication is more effective than MMT, they are treated more
like a patient than an addict, the treatment is very helpful, and they like the staff’s experience and concern for
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them. 22 In an in-depth qualitative study, patients were randomized to a general practice or an OTP. There was
an overwhelming preference for the general practice. 35 Three-fourths of the patients randomized to the OTP

ended up transferring to the general practice, yet none of the 16 patients randomized to the general practice

transferred to the OTP. Most patients who had prior MMT in an OTP would not go back to it and preferred the
general practice. In the general practice they felt like there was greater convenience with better overall care;
more respect, trust, and empathy from providers; increased autonomy, shared power, and responsibility; and
they were able to distance themselves from the drug scene, giving them a better environment for sobriety and
relapse prevention. 35 In all the studies, patients preferred being treated for their opioid addiction with their
primary care providers rather than going to a specialty clinic.

Barriers for OST Treatment in Primary Care
Six studies identified physician perceived barriers of providing OST in a primary care setting. They
ranged from 27 to 545 physicians surveyed. They were all descriptive survey studies but some asked open
ended questions while others were to mark multiple choice answers. The studies targeted different types of
providers, in limited areas of the country, and some had low return rates, therefore limiting generalizability.
The slow adoption of OST in primary care has influenced many researchers to investigate the barriers
preventing providers from offering this service and offer recommendations to reduce the treatment gap. Table 2Barriers for OST by Physicians, lists the detailed barriers each study evaluated and how strongly physicians felt
this was a barrier to them in prescribing OST in their personal practice. Not all of the barriers were identified in
every study and most of them compared providers who are prescribing OST to providers who are not
prescribing OST. In general, the physicians not waivered or not currently prescribing OST rated barriers higher
than physicians who were actively engaged in OST. Netherland (2009) states, “most factors that affect
willingness to prescribe buprenorphine are less significant for experienced prescribers than they are for
physicians new to buprenorphine treatment, suggesting that experience eases—at least in part—a number of

concerns”. 17(p249) This lack of experience or training for physicians was one of the most significant barriers
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identified. 10,11,17,19,29 There is limited attention given to teaching addiction medicine in medical school.13 On the

other hand, after completing the waiver course for buprenorphine, most physicians reported that they felt

prepared to prescribe buprenorphine, but would feel more comfortable if they had access to an expert mentor. 19
Consequently, limited access to mentor/expert or substance abuse counseling/mental health services is
identified as another significant barrier.10,13,17,19,29

Inadequate reimbursement is another barrier consistently listed by physicians; however, in most studies

it was not as significant as the lack of education. 10,11,17,19,29 This is one of the few barriers ranked higher by

prescribing physicians than those not prescribing. 17,37 One study mentioned that having financial incentives for

training and reimbursement would draw more physicians into the practice. 10 Expanding Medicare addiction

treatment coverage, as well as private insurance, would reduce that barrier. 10,17 Most patients who present for

this service are self-pay and research has shown that patients have higher retention rates if they have a source of
payment from insurance or a willing family member. 32 Then again, many patients enter treatment because the
cost of treatment, $300–$500/month in 2005 dollars, 32 is less than the cost of obtaining the drugs illicitly,
$800–$1200/month in 2006 dollars. 23

Administrative type barriers such as extra training, obtaining DEA waivers, record keeping

requirements, having access to buprenorphine or methadone medications, storage of the medications in their
office, and/or access to pharmacies that will dispense these drugs were also concerns for physicians. 10,11,13,17,19
Researchers also found a need for more access to nursing assistance with this process11,19 and mentioned the

need to hire an NP to follow and manage these patients to make treatment cost effective. 10 Some physicians

believe these patients will require a longer time to treat10,17 and their office is not set up to meet their treatment

needs.

The stigma of opioid dependent patients or concerns of compliance and diversion are mentioned in
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several studies. 10,11,13,17,19,29 The patients are labeled as difficult, demanding, time consuming, complaining, and
manipulative. Physicians worry that caring for this type of patient will bring a “street culture” into their clinic. 10
However, one recent study researched that barrier and found that most patients (12.1%) are unaware of the OST
prescribing status of the practice. Some (15.9%) would be likely to change practices if they did offer OST but
more would be likely to change due to other inconveniences like being kept waiting more that 30 minutes
(28.7%) or having a $10 increase in fees (26.6%).38 Some did not report this stigma specifically, but were
worried about lack of compliance, concern about diversion, 17,19,29 and a lack of interest among patients to be

treated for their opioid addiction.11,13,17

The 30 patients per practice limit was a significant barrier prior to 2007. 39 Current legislation allows

each physician in a practice to care for 30 patients during the first year and then increase to 100 patients when
the physician registers his intent to treat more. 39 This legislation has helped ease the treatment gap, but more
legislation is required if we are to truly overcome the barriers identified in the research.
Discussion
The population best served by office-based OST is current patients of primary care practices. They are
the patients who have become addicted to opiates through past injuries, chronic pain, or poor choices. Many
primary care providers are inadvertently treating their patient’s addiction with monthly opioid prescriptions for
their patient’s pain or other symptoms. These opioids are easily diverted by the patients and can be sold to buy
stronger opioids as their addiction spirals out of control. OST, in the primary care setting, gives providers an
option to help their patients with their addiction using a drug that is safer and harder to divert than traditional
opioids and in a treatment environment patients prefer. OST has been proven to be safe and effective in the
primary care setting and many opioid addicts are more willing to undergo treatment in a primary setting than an
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OTP. Health care providers now face overcoming the barriers that block this therapy from reaching those who
need it most.
“The goal of office-based treatment of opiate dependence is to improve access and reduce unmet

demand by bringing more people into treatment”. 40(p915) Research shows this goal is not met with our current

system. “Evaluations should be performed by policy-makers at regular intervals as an integral part of the policymaking cycle, but they should also be performed by outside evaluators in order to ensure accountability and
capture shortcomings”. 41(p221) It is time to identify where we can make changes to improve our current system
and meet the needs of Americans better.

NPs have been providing excellent primary care for several decades and many studies show that health
care outcomes for patients treated by NPs are comparable to care provided by physicians. 42,43 They provide

safe, quality, and cost effective care. 44 In fact, NPs received higher patient satisfaction scores and usually

provide more health advice when compared to physicians. 43,44 The Pearson Report (2009) found that NPs had
less malpractice and adverse actions and fewer convictions in comparison to both MDs and DOs.41Regulatory

barriers currently prevent NPs from handling the prescription-writing portion of opioid dependence treatment.
Although the Center for Substance Abuse Treatment-Substance Abuse and Mental Health Services

Administration (CSAT-SAMHSA) recommended in 2008 that future training initiatives and mentoring should
be expanded to other health care professional such as NPs, PAs, RNs, counselors, and certified nurse midwives,
they did not specifically mention that the prescriptive authority of NPs should be expanded. 41,43 Conversely, in
September 2011, the Association of Nurses in AIDS Care issued a position statement calling for extending
prescriptive authority to APNs:
Qualified APNs should be allowed to prescribe buprenorphine for the treatment of opioid dependence;
the DATA of 2000 should be amended to allow qualified APNs to prescribe buprenorphine; and
granting prescriptive privileges for buprenorphine to APNs will increase patient access to substance use
treatment. 44(p92)

If this barrier were removed NPs could serve opioid addiction populations in areas where there are physician
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shortages or where physicians are choosing not to treat this population. 41 Schackman et al. (2006) have
recognized the necessity of involving NPs in this prescriptive authority and state:

A policy research agenda for integrating buprenorphine into HIV primary care needs to address evidence
gaps in rationales that support some regulatory restrictions. In particular…the prohibition of the
prescription of buprenorphine by appropriately trained mid-level practitioner, such as physician
assistants and nurse practitioners, should be examined. 18(pS252)
Extending prescriptive authority for buprenorphine and allowing non-physician providers to become
waivered, will help to decrease the treatment gap in OST.4 Roose et al. (2008) found that non-physicians
(48.7%) were more likely to express interest in prescribing buprenorphine therapy than their physician
counterparts, generalist physicians (39%), or infectious disease specialists (27.2%).45 Many NPs are the sole

health care providers in underserved communities within states where they can practice independently, serving
vulnerable populations that do not have access to physicians. 43 Americans in these areas go without the life-

saving service of OST simply because NPs are prohibited from providing this service. 18 In areas where there is

access to physicians, the NPs and MDs can collaborate, support each other, and share resources, thereby

reducing many of the barriers holding back primary care providers from offering this service to their patients. 43
NP’s can help move this agenda by encouraging their professional organizations to join the Association of
Nurses in AIDS Care by creating position statements and start lobbying for legislation that would expand
prescription privileges to non-physician providers for OST. They can write letters to their legislators and
educate them about the necessity of this reform. They can also attend OST trainings and become better
educated with the options their patients have to treat this chronic and potentially deadly illness. This would
reduce the treatment gap and give most Americans who want and need this service access to OST.
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Conclusion

Most NPs deal with POA in their primary care practices. Rather than writing monthly prescriptions for
their patients with opioid dependence, NPs need to have the legal authority to identify their patients with opioid
addiction and inform them that they can help them get the problem under control. “Opioid-dependent
individuals need access to buprenorphine therapy and prohibition of prescribing by non-physicians restricts
their access to potentially life-saving treatment”. 41(p224) NPs want the legal authority to help overcome these

barriers, improve access, improve cost effectiveness, and reduce the “treatment gap” for people suffering from
opiate addiction.

Table 1- Demographics of Patients Entering OST at Primary Care Clinics

Age-median
Male
Caucasian
Full time
employment
Home Owner
>HS education
Years of opioid use
Prior treatment
Type of Drug use
Heroin
Prescription Drugs
Combination

Magura
2007
#19
N=86
38
74%
82%
58%

Barry,
2007
#37
N=142
35.8
80%
76.8%
85%

Sullivan,
2005
#34 N=96

6.7
59%

81.7%
7.8
64.8%

75%
10
46%

81%

38%
62%

28.8%
17.6%
53.6%

38
77%
68%
46%

94%
6%

Soeffing,
2009
#4 N=255
39.6
56.5%
45%

25.9%
83%
28.2%
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Table 2- Perceived Barriers for OST by Physicians

Perceived Barriers identified

Study

Netherland 2009 n=172
1=doesn’t affect at all
5= strongly affects *
Expert
Novice
Non-P
P
P
n=49
n=78
n=45

Kissin 2006 n=545
Detox= detoxification
Maint= maintenance **
P %
Non-P %
Detox/Maint
Detox/ Maint
n=241/218
n=60/58

McMurphy
2006
n=27

Non-P clinic
directors %

Sullivan 2006
n=257

% HIV
MD

%Non
-HIV
MD
n=144

Cunningham 2007
n=375

% with
waiver
n=94

% No
waiver
n=281

n=112
Stigma- being a difficult patient
93%
36.3%
45.4%
Lack of training for clinic staff
3.1
3.4
3.9
26%
Access to sub-abuse counseling
3.1
3.7
3.9
9.5%/16.1%
8.3%/12.1%
44%
Access to mental health service
3.0
3.8
3.7
Longer time for pt visit
3.3
3.4
3.6
56%
Availability of BUP/ methadone
3.2
3.5
3.8
27.4%/29.8%
25.0%/25.9%
26%
Effective referral system for
3.0
3.1
3.8
34.8%
48.1%
alternate drug treatment
Chronic pain treatment
3.0
3.5
3.8
No clinical guidelines available
2.5
3.1
3.7
Inadequate reimbursement
3.5
2.8
2.7
26%
9%
15%
24.2%
31.5%
Record keeping requirements
2.3
2.8
3.0
14.9%/15.1%
25.0%/25.9%
26%
9%
15%
Access to consult with expert
2.0
2.8
3.0
78%
82%
15.6%
23.1%
Extra training and DEA waiver
2.0
2.2
2.6
18.3%/22.9%
30.0%/37.9%
26%
9%
15%
Outside scope of expertise or lack
1.8
2.1
2.6
44%
9%
15%
44%
63.8%
of addiction experience MD
Difficult inductions logistics
1.7
2.4
2.7
31.1%/23.8%
25.0%/25.9%
Concern about diversion
2.0
2.2
2.5
9%
15%
40.4%
44.4%
Lack of interest among patients
1.7
2.1
2.5
11.2%/13.8%
11.7%/12.1%
Lack of patient compliance
13.7%/21.1%
23.3%/31.0%
8%
26.1%
34.7%
Lack of interest among provider
1.9
1.8
2.2
26.7%
31.5%
Prefer alternate treatment
1.6
1.8
2.1
Effectiveness not demonstrated
1.3
1.4
1.8
Patient side effects
7.9%/5.5%
6.7%/5.2%
46%
Bringing street culture to office
48%
Need more nurses or NP support
44%
8%
Time and $ for MD training
26%
Increased legal risks
28.9%
46.4%
Lack of institutional support
n=number of MD’s surveyed
P=MD’s who currently prescribe OST
Non-P=MD’s who do not prescribe OST or have stopped prescribing it
*Netherland used a 1-5 Likert scale with 1 (doesn’t effect at all) to 5 (strongly affects)
**Kissin compared MD’s who did detoxification (Detox) from opioids only to those who prescribed long term maintenance therapy (Maint)

Walley 2008
n=235

P%
n=156
7%
7%

Non-P
%
n=79
0%
22%

12%

1%

21%

10%

3%

3%

2%

18%

16%

27%

12%

24%

13%

30%
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